|
Title
|
Publication Date
|
Price
|
Relevance
|
Antihypertensives
Competitor Analysis
|
Jun 2008 |
£250 |
100% |
|
Report on Antihypertensive Drug Market
|
May 2009 |
£350 |
99% |
Commercial Insight: Antihypertensives
New challenges for a maturing market
|
Sep 2006 |
£8,365 |
96% |
Antihypertensives Market to 2016
Generic Erosion Following Patent Expiry of Major ARBs to Impact the Market
|
Dec 2010 |
£2,215 |
95% |
|
U.S. Market for Nutritional Solutions in Immune and Antihypertensive Health
|
Dec 2010 |
£4,300 |
94% |
|
European Market for Nutritional Solutions in Immune and Antihypertensive Health
|
Mar 2011 |
£4,300 |
94% |
|
Analysis of Cardiovascular Drugs Market in Saudi Arabia and the United Arab Emirates
|
Jul 2011 |
£3,795 |
90% |
World Market for Prescription Cardiovascular Drugs
2nd Edition
|
Nov 2007 |
£2,525 |
86% |
|
Global Cardiovascular Drugs Market 2009-2024
|
Jun 2009 |
£1,499 |
85% |
Diabetes and Diabetic Complications
Major World Markets, 3rd Ed.
|
Mar 2007 |
£2,525 |
85% |
|
Cardiovascular Drugs
|
Apr 2010 |
£2,815 |
84% |
Glomerulonephritis Therapeutics
Pipeline Assessment and Market Forecasts to 2017
|
Mar 2011 |
£1,265 |
78% |
The Cardiovascular Market Outlook to 2016
Healthcare
|
Jun 2011 |
£2,425 |
75% |
|
Latin American Cardiovascular Drugs Markets
|
Jan 2008 |
£5,015 |
74% |
|
Drug Treatments for Leading Endocrine and Metabolic Diseases
|
Jan 2007 |
£2,760 |
72% |
Brain Hemorrhage Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Nov 2011 |
£2,215 |
70% |
|
Stroke: Competing Treatments and Market Entry Considerations
|
Jun 2010 |
£2,500 |
64% |
Generic Competition, 2009 to 2013
The impact of patent expiries on sales of major drugs
|
Apr 2009 |
£995 |
63% |
Pediatric Drugs: the Worldwide Market
3rd Edition
|
Dec 2007 |
£2,525 |
63% |
Antithrombotics
Competitor Analysis
|
Jul 2008 |
£415 |
62% |
Cardiovascular Drug Delivery
Technologies, Markets and Companies
|
Jan 2012 |
£1,815 |
57% |
|
World Market for Diabetes Treatments, The
|
Oct 2010 |
£1,895 |
53% |
|
Astellas Pharma Inc.: PharmaVitae Profile
|
Jun 2010 |
£3,605 |
52% |
|
Hypertension: Competing Treatments and Market Entry Considerations
|
Jun 2010 |
£2,500 |
51% |
21st European Meeting on Hypertension and Cardiovascular Prevention 2011
Post-Conference Review and Analysis
|
Jun 2011 |
£630 |
51% |
|
Pharmaceuticals in China
|
Feb 2006 |
£3,035 |
50% |
|
Blood Pressure Monitoring & Measurement Instruments
|
Oct 2010 |
£2,655 |
47% |
Chronic Kidney Disease (CKD) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Sep 2011 |
£2,215 |
46% |
|
Innovations in Cardiovascular Disease Management: Latest surgical procedures, drugs and medical devices
|
Sep 2007 |
£1,820 |
46% |
Peripheral Artery Disease (PAD) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Nov 2011 |
£2,215 |
46% |
